Antithrombotic Therapy to Minimize Total Events After Acute Coronary Syndrome (ACS) or Percutaneous Coronary Intervention (PCI) in Atrial Fibrillation: Insights From AUGUSTUS
Authors' conclusion
Among patients with AF and recent ACS or PCI, apixaban significantly reduced total bleeding risk compared with VKA. Aspirin doubled total bleeding risk compared with placebo without a significant change in total ischemic events.
Study context
- Population
- Patients with atrial fibrillation (AF) and recent ACS or PCI on P2Y12 inhibitor therapyrandomized
- Participants
- 4,614 patients
- Comparison
- Apixaban vs vitamin K antagonist (VKA) and aspirin vs placebo
- Primary endpoint
- Total major or clinically relevant nonmajor bleeding events, total ischemic events and total hospitalizations
- Follow-up
- 6 months
Methodological detailsopen-label, 2×2 factorial
- Open-label
- 2×2 factorial
Primary result
As reported in the abstract
Total bleeding
Relative risk (95% CI)
Apixabanvs VKA
0.66(0.55–0.80)
Aspirinvs Placebo
2.14(1.75–2.60)
Further findings
| Outcome | RR (95% CI) | |
|---|---|---|
| Total ischemic eventsApixabanvs VKA | 0.83 (0.58–1.20) | |
| Total ischemic eventsAspirinvs Placebo | 0.75 (0.52–1.08) | |
| Total hospitalizationsApixabanvs VKA | 0.90 (0.79–1.03) | |
| Total hospitalizationsAspirinvs Placebo | 1.11 (0.97–1.27) | |
| 0.512Relative risk (log scale) |
- Total ischemic events: ≥1 ischemic event: 219 (4.7%); 75 (34.2%) of them multiple
- Total hospitalizations: ≥1 hospitalization: 1,125 (24.4%); 384 (34.1%) of them multiple
Original publication
Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →